NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
CompletedN/A
Sponsor: Hoffmann-La Roche
Conditions: Rheumatoid Arthritis
Interventions: TNF inhibitor/TCZ
Countries: Sweden
This six months non-interventional, observational, post-marketing, multi-center and local study will evaluate the differences in the use of corticosteroids between RA participants receiving TCZ or a TNF-inhibitor, in participants who have discontinued the use of a TNF-inhibitor as their first biological treatment.
Eligibility overview
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: * At least 18 years of age. * With a diagnosis of moderate to severe RA according to the revised (1987) American College of Rheumatology (ACR) criteria or 2010 ACR/ European League Against Rheumatism (EULAR) RA classification criteria. * Have had an insufficient response or intolerance to their first TNF-inhibitor (including biosimilars for TNF-inhibitors). * The treating physician has made the decision to commence TCZ or TNF-inhibitor treatment. Participants need to have a Disease Activity Score (DAS) 28 assessment at initiation of their second biological treatment. * Have been given oral and written information about the study and have no objection to the data concerning him/her being subject to computerized data processing, have given informed consent. Exclusion Criteria: * Have had more than one TNF-inhibitor prior to the enrolment visit. * Have had biological treatment other than TNF-inhibitors. * Participants that are continuously treated with per oral corticosteroids for any other indication than RA (at baseline).
Locations (11)
- Arvika, Sweden
- Eskilstuna, Sweden
- Huddinge, Sweden
- Karlskrona, Sweden
- Malmö, Sweden
- Malmö, Sweden
- Örebro, Sweden
- Skövde, Sweden
- Stockholm, Sweden
- Trelleborg, Sweden
- Uppsala, Sweden